Riskpilot← Back to searchSign inGet full accessNORNSPHARMA AS
ASActiveOrg 921668570Sørkedalsveien 5C, 0369 OsloRetail sale of cosmetic and toilet articles · NACE 4775Est. 20180 employees
Revenue 2025
NOK 0
EBITDA margin
—
Equity ratio
—
Financial strength
Net profit 2025
NOK -5K
0 employees
| Revenue | NOK 0 | — |
| EBITDA | NOK -5K | — |
| Net profit | NOK -5K | — |
| Total assets | NOK 0 | — |
| Equity | NOK -60K | -9% |
| Employees | 0 | — |
Legal name
NORNSPHARMA AS
Org number
921668570
Legal form
Aksjeselskap
NACE code
4775 · Retail sale of cosmetic and toilet articles
Founded
5. november 2018
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Forskning og utvikling av naturprodukter, mat, helseprodukter, produksjon, innkjøp og salg, internasjonal handel, engroshandel med ulike produkter, og annen virksomhet knyttet til dette, herunder deltakelse i andre virksomheter.
Address
Sørkedalsveien 5C, 0369 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 6 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −19 | −10 | −11 | −21 | 0 | 0 | −5 |
| Depreciation & amort. | −0 | −0 | −0 | −19 | −0 | −0 | −0 |
| EBIT | −19 | −10 | −11 | −39 | 0 | 0 | −5 |
| Net financials | 0 | −0 | 0 | −0 | 0 | 0 | 0 |
| Profit before tax | −19 | −10 | −11 | −40 | 0 | 0 | −5 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −19 | −10 | −11 | −40 | 0 | 0 | −5 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total assets | 35 | 64 | 64 | 0 | 0 | 0 | 0 |
| Equity | 5 | −5 | −16 | −55 | −55 | −55 | −60 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 30 | 69 | 80 | 55 | 55 | 55 | 60 |
| Total debt | 30 | 69 | 80 | 55 | 55 | 55 | 60 |
EBITDA margin
-484900.0%
This company
15.8%
Market median
-3069087% vs market
20192025
Equity ratio
-6030900.0%
This company
38.2%
Market median
-15787796% vs market
20192025
Return on equity
-484900.0%
This company
18.4%
Market median
-2635426% vs market
20192025
Net profit margin
-484900.0%
This company
8.1%
Market median
-5986520% vs market
20192025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192025
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20192025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2018 | — | — | |
| Chairman | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
REGNSKAPSHUSET AS | Company | 100.0% | 100.0% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Rh Partner Invest As
NORNSPHARMA AS Board members of NORNSPHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Willy Saar Pedersen | Chairman | 0 companies |
| Lars Herman Lindkjølen | Chairman | 0 companies |